Latest

neuropharmacology

·July 17, 2023·4 min read

Anti-Inflammatory Drugs: A Pathway to Alzheimer’s Treatment

A new study sheds light on how certain anti-inflammatory drugs may prove to be effective treatments for Alzheimer's disease (AD). The team zeroed in on a protein known as p38.

Featured Neurology Neuroscience

·July 1, 2023·6 min read

Lecanemab Alzheimer’s Treatment Set for FDA Approval

Doctors are preparing to administer lecanemab, a promising new Alzheimer's disease treatment nearing FDA approval. This therapy, marketed as Leqembi, slows cognitive decline by extracting amyloid proteins from the brain, thus decreasing tau protein accumulation.

Featured Neuroscience Psychology

·June 16, 2023·6 min read

Psychedelic Breakthroughs: Balancing Promise and Peril in Mental Health Therapies

Psychedelics offer promise as potential treatments for mental health disorders, from depression to PTSD. However, the unique mind-altering effects of these substances also present distinct ethical and clinical challenges.

Featured Neuroscience

·June 13, 2023·5 min read

Unveiling a Cognitive Booster Hidden in a Laxative

A new study has investigated how the laxative prucalopride, known to activate serotonin receptors, affects resting brain activity in healthy adults. The study discovered that those who took prucalopride demonstrated increased functional connectivity between major cognitive networks in their resting-state.

Featured Neurology Neuroscience

·June 13, 2023·5 min read

Antihistamine Sparks Hope for Myelin Repair in Multiple Sclerosis

A new study paves the way for potential treatments for Multiple Sclerosis (MS) by identifying the OTC antihistamine, clemastine, as an effective drug for brain repair. Utilizing a newly-developed MRI scan technique, scientists were able to observe and measure the impact of clemastine on brain myelin levels.

Brain Cancer Featured Neuroscience

·June 4, 2023·6 min read

Targeted Therapy Vorasidenib Offers Hope for Deadly Brain Tumors

A newly developed drug, Vorasidenib, has shown promise in prolonging progression-free survival for patients with a subtype of glioma. The international study found that patients taking Vorasidenib could go nearly 17 more months without their cancer worsening, postponing the need for radiation and chemotherapy.

Brain Cancer Featured Neurology Neuroscience

·June 2, 2023·6 min read

Promising Phase 2 Trial Results for Pembrolizumab in Metastatic Brain Cancer

A phase 2 clinical trial of pembrolizumab has shown promising results, with 42% of patients with metastatic brain cancer benefiting from the treatment. The trial found that pembrolizumab, an immunotherapy, was tolerated and demonstrated clinical benefit in patients with brain metastases.

Featured Neurology Neuroscience

·May 19, 2023·5 min read

Is the BCG Vaccine a Potential Shield Against Alzheimer’s?

A recent study suggests that the Bacillus Calmette-Guérin (BCG) vaccine, typically used to prevent tuberculosis, may also reduce the risk of Alzheimer's disease and related dementias. The study followed 6,467 individuals, over 15 years post their diagnosis with non-muscle-invasive bladder cancer. Findings revealed patients who received the BCG vaccine had a 20% lower risk of Alzheimer’s disease and related dementias, and a 25% reduced risk of death.

Brain Cancer Featured Neurology Neuroscience

·May 12, 2023·6 min read

Common Seizure Drug Blocks Deadly Brain Cancer Growth

Researchers discovered a promising new avenue for treating glioblastoma, a deadly brain cancer. The study found that these tumors restructure connections in surrounding brain tissue, leading to cognitive decline. The team discovered that the drug gabapentin, commonly used to prevent seizures, could inhibit this activity in mice with glioblastoma.

Featured Neurology Neuroscience

·May 10, 2023·5 min read

Alzheimer’s Drug Lecanemab Shields Brain from Free-Roaming Amyloid Fibrils

Researchers have unveiled the structure of a unique amyloid beta protein associated with Alzheimer's progression. This protein forms small aggregates that disrupt brain function. Importantly, the study found that lecanemab, a recently FDA-approved Alzheimer's treatment, can neutralize these disruptive aggregates, hinting at its potential to slow down the disease's cognitive decline.

Featured Neuroscience Visual Neuroscience

·May 8, 2023·5 min read

Eye-Opening Drug Discovery May Help Treat Age-Related Macular Degeneration

350 million people worldwide are believed to suffer from blinding diseases including age-related macular degeneration and diabetic retinopathy. Researchers have discovered a small class of drugs, dubbed SREDs, that have the potential to treat a range of blinding diseases.

Featured Neurology Neuroscience

·May 3, 2023·3 min read

Alzheimer’s Drug Donanemab Slows Cognitive and Functional Decline in Phase 3 Study

Findings from a Phase 3 study show donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease. Donanemab met the primary endpoint of change, which measured measures cognition and activities of daily living such as managing finances, driving, engaging in hobbies, and conversing about current events, from baseline until 18 months on the integrated Alzheimer's Disease Rating Scale (iADRS). All secondary endpoints of cognitive and functional decline were also met and showed highly statistically significant clinical benefits with similar magnitude. Results suggest that people in the early pathological stage of Alzheimer's could be the most responsive to therapeutics targeting amyloid.